The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.

Over the past 10 years, cancer immunotherapy has made significant progress in multiple cancer types and has been gradually been applied to clinical cancer care, in which the programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway is one of the most attractive targets. Compared with traditional therapies, the emerging PD-1/PD-L1 blockade immunotherapy exhibited more satisfactory curative effects and lower toxicity for patients with advanced head and neck squamous cell carcinoma (HNSCC). This review analyzes the expression characteristics and clinical significance of PD-1/PD-L1 in HNSCC, the immunosuppressive roles of tumor cell and stromal cell expressing PD-1/PD-L1 in this disease, and presents the development landscape of PD-1/PD-L1 inhibitors, which may provide new curative alternatives for recurrent or metastatic HNSCC.

Introduction

Head and neck cancers (HNC) are the sixth most common malignancies worldwide, with more than 680,000 new cases diagnosed every year (1, 2). Due to various carcinogenic factors, such as smoking, alcohol abuse, human papillomavirus (HPV) infection, and extended life expectancy, the incidence of HNC is rising year by year, of which the most frequent pathological type is squamous cell carcinoma (3). Although traditional therapies, including surgery, radiotherapy, and chemotherapy have made some progress in recent years, the prognosis for HNSCC patients remains unsatisfactory, with a 5-years survival rate of ~50% (4). More than 50% of HNSCC patients have had tumor recurrence and metastasis within 3 years (5). Therefore, it is necessary to optimize therapeutic regimes to improve the outcome of this disease. Over the past 10 years, cancer immunotherapy has made significant progress and has gradually been applied to clinical care in multiple cancer types. Various immunotherapeutic methods for HNSCC are under investigation, such as immune checkpoint inhibitors (ICIs), tumor vaccines, cell-based therapies, and cytokines therapy (6–8). At the same time, immunotherapy combined with other traditional therapies has also achieved improved curative effects for HNSCC patients in various clinical trials, which indicates that the clinical care of HNSCC is entering a new era (9–11).

Compared with the traditional treatments, the up-and-coming anti-PD-1/PD-L1 agents present better efficacy and lower toxicity for patients with advanced HNSCC (12–15). Based on the results of the clinical trial KEYNOTE-048, on June 10, 2019, the U.S. Food and Drug Administration (FDA) approved the PD-1 monoclonal antibody pembrolizumab (Keytruda) as the first-line therapeutic drug for patients with metastatic, unresectable, and recurrent HNSCC. Besides, FDA recommended Pembrolizumab in combination with platinum and fluorouracil for all advanced HNSCC patients, and as monotherapy for patients whose PD-L1 expression Combined Positive Score (CPS) is ≥1% (16). However, unlike Hodgkin's lymphoma in which the objective response rate (ORR) is as high as 87%, the ORRs of nivolumab and pembrolizumab are only 15% for HNSCC, indicating that much more effort should be made to investigate the pattern and mechanisms of PD-1/PD-L1 expression in HNSCC (17). And treatment-related adverse events have happened to over 50% of patients, which also impacted clinical outcomes (18). Herein, this article analyzes the expression characteristic and clinical significance of PD-1 and PD-L1 in HNSCC, focuses on how tumor cells and stromal cells expressing PD-1 and PD-L1 play immunosuppressive roles in HNSCC, and reviews the present development landscape of PD-1/PD-L1 inhibitors, which may be useful to HNSCC patients with recurrence and metastasis.

Expression Features of PD-L1 and PD-1 in HNSCC

Belonging to the CD28 family, PD-1 (CD279) is one of the T-cell co-inhibitory receptors, expressing on various immune cells, such as activated T cells, regulatory T cells (Tregs, CD4+ Foxp3+), natural killer cells (NK cells), activated B cells and macrophages (19). PD-1 has two known ligands, PD-L1(B7-H1/CD274) and programmed cell death ligand 2 (PD-L2/CD273), from which PD-L1 is mainly expressed on T cells, B cells, dendritic cells (DCs), and macrophages (20, 21). Moreover, PD-L1 is also expressed in non-immune cells, such as cornea cells, vascular endothelial cells, mesenchymal stem cells, and keratinocytes, and it is often inducibly or constitutively upregulated on tumor cells of lots of solid and hematologic tumors (20). Interestingly, PD-L1 has been found in a soluble form (sPD-L1) in the patients' serum with tumors, such as melanoma and lung adenocarcinoma (22–25). Theodoraki et al. also demonstrated that sPD-L1 was found in plasma of patients with HNSCC (26). Besides, PD-L1 also binds to CD80 (B7-H1), which delivers inhibitory signals in T cells (27, 28). The expression of PD-L2 is more restricted to antigen-presenting cells (APCs), such as dendritic cells, macrophages, and B cells (29, 30). Similar to PD-L1, PD-L2 inhibits T-cell activation, decreases cytokine production, and induces T-cell cytolysis (31, 32). Nevertheless, in most cases, the PD-L2 expression was not detected in HNSCC tumor parenchyma according to Yearley et al. and Schoenfeld et al. (29, 33).

The over-expression of PD-L1 in tumor cells results from intrinsic and extrinsic regulatory mechanisms, in which IFN-γ secreted by immune cells is the most known potent cytokine inducer (34). A study found that human oral squamous cell carcinomas (OSCC) cell lines expressed various levels of PD-L1, and IFN-γ stimulation up-regulated PD-L1 expression on OSCC cells (35). Chen et al. found that IFN-γ induced PD-L1 expression by upregulating protein kinase D isoform 2 (PKD2), a downstream target of phosphoinositide 3-kinase (PI3K), in a time and dose dependent manner in OSCC cells (36). And inactivation of tumor suppressor gene phosphatase and tensin homolog (PTEN), which was often observed in human SCC, has been related to enhanced PD-L1 expression in lung SCC, representing the intrinsic mechanism of PD-L1 expression in tumors (37). Additionally, Chen et al. demonstrated that CMTM6, a type-3 transmembrane protein, induced PD-L1 expression in HNSCC cells and reduced CD8+ and CD4+ T cell infiltration (38). Others demonstrated that CMTM6 protected PD-L1 from ubiquitination in tumor cells and increased PD-L1 protein half-life (39, 40). At present, more attention has been paid to the intrinsic regulatory mechanism of PD-L1 expression on tumor cells.

Immunostaining of PD-1 shows high levels in inflammatory cells of HNSCC, especially at the invasive front of the tumor (41). In HNSCC tissues, PD-L1 showed both membrane and the cytoplasm staining by immunohistochemistry (IHC) (42). Besides, both tumor parenchyma and stroma showed PD-L1 expression, and increased PD-L1 expression in tumor parenchyma was associated with increased stromal expression (33). The expression of PD-L1 has two patterns, diffuse staining throughout tumor parenchyma from an overview of the tumor, or peripheral staining around tumor parenchyma. The majority was peripheral staining on both tumor cells and tumor-associated macrophages (TAM), especially in front of tumor parenchyma, which may be related to the inflammatory microenvironment and invasion front of HNSCC (43, 44). The degree of PD-L1 expression in HNSCC tissues is varied from study to study, which may be for several reasons, such as different protocols for immunohistochemical staining, different antibodies with varying binding affinities, the inconsistent cut-off for positivity, biopsy quality, subjective factors of pathologists' evaluation and intratumor heterogeneity (45). These studies are shown in Table 1.

Table 1

PD-L1 positivity in HNSCC of previous studies.

Study	Sample size	Cut-off of PD-L1 positivity	% Positive	% Positive in HPV+ vs. HPV−	Tumor types
Lyford-Pike et al. (44)	27	5% of tumor cells	59%	70 vs. 29%	Oropharyngeal SCC
Kim et al. (46)	133	20% membrane staining of tumor cells	68%	61 vs. 71% (p = 0.274)	Oropharyngeal SCC
Hong et al. (49)	99	Any unequivocal membrane staining of tumor cells	69.7%	83.3 vs. 56.9%	Tonsillar cancer
Mattox et al. (43)	53	1% membrane staining of tumor and/or immune cells	79%	Not reported	Tougue SCC
Balermpas et al. (48)	161	5% of tumor and/or stromal cells	39.1%	53 vs. 31%	HNSCC (including oral cavity, oropharynx, and hypopharynx)
Ou et al. (47)	38	1% on both tumor and immune cells 5% on both tumor and immune cells	71.1% 50%	No significant relationship	HNSCC (multiple sites)

With HPV infection becoming a cause of a subset of HNSCC, of which the incidence is increasing year by year, many studies intent on finding out how the immune microenvironment of HPV-positive tumors is different from HPV-negative tumors, including the expression differences of PD-L1. Although few studies found no correlation between PD-L1 and HPV positivity (46, 47), most have indicated that PD-L1 expression levels are positively related to HPV infection (33, 44, 48–50). Moreover, a meta-analysis showed that PD-L1 positive expression accounted for 42% of 3,105 HNSCC patients and was associated with HPV status (51). These results suggest that PD-1/PD-L1 pathway plays a specific role in the pathogenesis and development of HPV-positive HNSCC.

Biological Significance and Prognosis Value of PD-1/PD-L1 Axis in HNSCC

Since the PD-1/PD-L1 pathway is involved in immune evasion and tumor progression, many researchers have conducted in-depth research into whether the expression level of PD-1 and PD-L1 protein in tumor tissues is related to the clinical characteristics and biological behavior of HNSCC. However, the current results are still controversial. Some researchers concluded that stronger PD-L1 immunostaining in HNSCC tissues correlates with distant metastases and worse outcomes, independent of tumor origin (52). Similarly, Moratin et al. found that higher PD-L1 expression in OSCC was associated significantly with tumor size, clinical stage, regional metastases, as well as worse overall survival (OS) (53). Additionally, levels of PD-L1 that carried by circulating exosomes were positively correlated with the UICC stage and the lymph node status of HNSCC, indicating that PD-L1 expression in circulating exosomes may also be a metric for HNSCC (26).

On the contrary, others reported that higher PD-1/PD-L1 expression predicted a better outcome, with significantly fewer local and distant recurrences which was particularly prominent in HPV-positive patients (48, 54). In a study of tonsillar cancer, patients with both HPV and PD-L1 positivity had longer progression-free survival (PFS), OS, and lower risk of death (49). It was reported that HPV-positive HNSCC patients had high PD-1 expression, and the PD-1 high group in these patients who treated with radiotherapy had better recurrence-free survival (55). And the therapeutic response to immunotherapy was better in HNSCC patients with higher PD-L1 expression (56). Thus, the better outcome of PD-1-PD-L1+ HNSCC patients may be a result of better response to radiotherapy and immunotherapy.

However, Kim et al. reported that PD-L1 expression of tumor cells is not related to the clinical characteristics and prognosis of HNSCC patients (46). HNSCC patients whose tumor cells do not express PD-L1 still respond to treatment, which demonstrates that PD-L1 or PD-1 expression on non-tumor cells plays a specific role. A meta-analysis of PD-L1 expression detected by IHC in predicting survival of HNSCC patients suggested no significant difference in OS between PD-L1-positive and -negative HNSCC patients (51). While for patients with low CD8+ tumor-infiltrating T cells, a poorer OS was detected in those with positive PD-L1 expression than those with negative PD-L1 expression, showing that PD-L1 expression on immune cells rather than tumor cells was associated with a better outcome for HNSCC (51, 57). In a study of nasopharyngeal cancer, PD-1 expression was higher in CD8+ TILs than that in healthy tissues and correlated with poor prognosis (58). These indicated that PD-L1 or PD-1 expression on non-tumor cells may be useful for guiding treatment of HNSCC and the prognostic role of PD-L1 expression combined with immune cells infiltrating should be further investigated.

HPV infection can affect the host immune response and immune activation in HNSCC. Recent research has found that HPV-positive HNSCC showed a higher level of PD-1 mRNA and increased PD-1+ T cells, while the latter was associated with worse outcomes (59–61). However, Poropatich et al. found that a higher proportion of PD-1+ CD8+ T cells and cytotoxic T lymphocyte antigen 4 (CTLA-4)+ CD8+ T cells were present in the tumor tissues and peripheral blood of HPV-negative HNSCC, and PD-1+ CD8+ T cells were related to primary tumor size (62). Sufficient PD-1+ T cells subset represented the previous activation state of T cells against tumors, which could be reactivated by PD-1/PD-L1 blockade (57). Additionally, a histoepigenetic analysis showed that HPV-positive HNSCC had a higher level of both infiltrated CD8+ T and B cells in the tumors as well as higher PD-1 expression in immune cells, which may lead to a better response rate by PD-1 targeted therapy (63).

These inconsistent conclusions give cause for consideration. Some researchers pointed out that the extent of PD-1 expression rather than the frequency determined T-cell function and affected clinical outcome and response to PD-1/PD-L1 inhibitors. CD8+ TILs in HPV-negative HNSCC were mostly characterized by high-density of PD-1 expression, which symbolized a state of dysfunction accompanied by suppressed IFN-γ secretion, associating with worse disease-free survival (DFS) and higher hazard ratio for recurrence. In contrast, low-density PD-1 was predominantly expressed in T cells of HPV-positive HNSCC patients, who had a better outcome (64). Overall, recent research has been mainly focused on PD-1 or PD-L1 expression in tumor cells and T cells of HNSCC, but little is known in NK cells, macrophages, B cells, DCs, or other stromal cells.

Mechanisms of the PD-1/PD-L1 Pathway in Tumor Evasion of HNSCC

Studies have suggested that immune cell dysfunction within the tumor microenvironment with HNSCC resulted in immunosuppression (8, 65). PD-1/PD-L1 axis participates in modulating immune cells and other stromal cells and has been proposed as a potential mechanism for the formation of this immunosuppressive microenvironment, further facilitating immune evasion and immune resistance (Figure 1).

Figure 1

This figure shows the immunosuppressive microenvironment mediated by PD-1/PD-L1 pathway. CAF, Cancer-associated fibroblasts; TAM, Tumor-associated macrophages; Treg, regulatory T cells. (A) PD-L1 on tumor cells combines with PD-1 on cytotoxic T cells transmits an inhibitory second signal to T cells, causing effector T cells exhaustion, dysfunction and tumor progression. At the same time, PD-L1 can act as a ligand to bind with CD80 on effector T cells, competitively inhibits the binding of costimulatory molecule CD28 with CD80, and hinders T cell activation. (B) PD-L1 also binds to PD-1 on Tregs, resulting in immune suppression by raising the threshold for T-cell activation. (C) For NK cells, PD-1 represents an “activated” phenotype and binds to PD-L1 on tumor cells or stromal cells, leading to its dysfunction. (D) Activation of PD-1 signals on B cells can inhibit the proliferation of CD4+ and CD8 T+ cells. (E) Activated CD4+ T helper cells modulated the up-regulation of PD-L1 expression on macrophages via IFN-γ, and TAMs could mediate adaptive resistance and dampen tumor specific T cell function based on PD-L1 expression. (F) HNSCC tumor cells recruit fibroblasts and up-regulate PD-L1 expression on fibroblasts. Conversely, fibroblasts can increase PD-L1 expression on HNSCC cells. (G) PD-L1 on tumor cells binding with PD-1 can transmit anti-apoptotic signals to the tumor themselves. (H) PD-1 antibodies can competitively inhibit the binding of PD-1 to PD-L1, while PD-L1 antibodies bind to PD-1, and they both inhibit the activation of the PD-1/PD-L1 signal pathway and reverse the suppressive effect.

T Cells

Inhibitory immune-checkpoint receptors (ICRs), such as PD-1, CTLA-4, and T cell Ig and mucin domain-3 protein (Tim-3), are considered to represent an exhausted and inactivated T cell phenotype in HNSCC (66, 67). Not only that, but PD-1 is also expressed in varying degrees on draining lymph nodes, circulating CD4+ and CD8+ T cells (68). Expression levels of various immune regulatory molecules, such as OX40, PD-1, PD-L1, and CTLA-4, are always higher in TILs than those in peripheral blood lymphocytes (PBL) (44, 69, 70).

APCs present antigens to T cells through the T cell receptor (TCR) and activate T cells. Binding of PD-L1 with PD-1 on activated T cells blocks PI3K and Akt activity, disrupts glucose metabolism and suppresses Th1 cytokines production, which could induce effector T cells dysfunction, exhaustion and protect tumor cells from being killed by CD8+ T cells (cytotoxic T cells) (71, 72).

Recent studies show that intratumoral Tregs suppress anti-tumor immunity and is involved in tumor progression. Compared with peripheral Tregs, inhibitory receptors PD-1, CTLA-4, and Tim-3 were significantly increased in tumor-infiltrated Tregs in HNSCC, signifying more suppressive function (59, 70). The interaction between PD-L1 and PD-1 on Tregs enhances the proliferation of Tregs and promotes the development of Tregs, leading to immune suppression by raising the threshold for T-cell activation. In the presence of transforming growth factor-β (TGF-β), PD-L1 can promote the conversion of naive CD4+ T cells to Tregs simultaneously improve the suppressive capabilities of the latter (73, 74). And recent research indicated that PD-1 expression on Tregs represents a state of “exhaustion,” and such Tregs were less suppressive. Tim-3 is also a regulatory molecule on intratumoral Tregs and represents the activation state of Tregs, which inhibits T cell proliferation. Furthermore, PD-1/PD-L1 blockade down-regulated the expression of Tim-3 on Tregs isolated from murine HNSCC tumors, which may be related to the release of IFN-γ (75).

NK Cells

NK cells are of great importance in connecting innate and adaptive immunity, and also play a vital role in anti-tumor immunity. It was reported that HNSCC patients have high levels of PD-1+ NK cells within the tumor and peripheral blood. PD-1 expression on NK cells represents the activation status, and cetuximab-mediated NK cell activation can up-regulate PD-1 expression. However, once bound to its ligand PD-L1, such activation state is inhibited. In turn, PD-1 blockade can enhance cetuximab-mediated antibody-dependent cytotoxicity (ADCC), thus resulting in HNSCC cell lysis (76). Makowska et al. found that PD-1 blockade increased cytotoxicity of IFNβ-activated NK cells toward nasopharyngeal carcinoma cells, which resulted from the secretion of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) (77).

TAMs

TAMs are critical infiltrated inflammatory cells for cancer promoting inflammation (78). PD-L1 expression on macrophages delivers a constitutive negative signal, resulting in an immune-suppressive cell phenotype and contributing to the immune-suppressive tumor microenvironment (79). In a study on oral tongue squamous cell carcinoma (OTSCC), activated CD4+ T helper cells up-regulated PD-L1 expression on macrophages via IFN-γ (43). PD-L1 expression may provide a means to protect macrophages or DCs from cell death in OSCC (80). Besides, OSCC tumor cells induced PD-L1 expression on TAMs via IL-10 and led to T cell apoptosis and unfavorable prognosis (81, 82). Also, in HPV-positive HNSCC, TAMs could mediate adaptive resistance and dampen tumor-specific T cell function based on PD-L1 expression at the interface between the tumor nests and the surrounding inflammatory stroma (44). In turn, PD-L1 expression on tumor cells can be induced by macrophages in HPV-positive HNSCC (83).

Cancer-Associated Fibroblasts (CAFs)

As part of tumor stromal cells, CAFs have received much attention in recent years and correlate with tumor invasion and metastasis. They secrete various growth factors, chemokines and proteases to regulate and recruit innate and adaptive immune cells. PD-L1 is also expressed on CAFs, and it has been reported that 40% of HNSCC tissues showed PD-L1 positivity on CAFs but showed no clinical significance (84). Baruah et al. found that HPV-positive HNSCC tumor cells recruited fibroblasts and up-regulated PD-L1 and PD-L2 expression on fibroblasts via the TLR9-mediated mechanism. Conversely, fibroblasts can increase PD-L1 expression on HPV-positive HNSCC cells (83). Nazareth et al. demonstrated that PD-L1 expressing human non-small cell lung cancer associated fibroblasts could inhibit the activation of T cells, and it could be completely abrogated by PD-L1 blockade (85). And research also suggested that TGF-β could induced human and murine lung fibroblasts PD-L1 expression, and further inhibited T cell proliferation in response to T cell receptor stimulation through secreting exosomes that contained PD-L1 (86). It is known that PD-L1 overexpression could induce T-cell apoptosis in tumor (87). Therefore, there is a mutual interaction between tumor cells and stromal cells, which finally increases the overall PD-L1 level, creating an immune-suppressive microenvironment. However, at present, whether PD-L1+ CAFs modulate T cell activity through direct contact or secreting cytokines is still unclear. Thus, the underlying mechanisms of PD-L1 induced or expressed by CAFs participating in remodeling the inflammatory microenvironment in HNSCC still need further investigation.

Tumor Cells

A population of CD44+ tumor cells exists in HNSCC, which are considered “cancer stem cells” and are associated with tumorigenesis and resistance to chemo- or radiotherapy (88). Lee et al. found that CD44+ tumor cells preferentially expressed PD-L1 on CD44+ tumor cells rather than CD44− cells, and was less immunogenic when cocultured with expanded autologous CD8+ TILs. While the impeded immunogenicity of CD44+ cells was reversed by PD-1 blockade. These suggested CD44+ tumor initiating cells could evade immune surveillance by expressing PD-L1 (89).

Exosomes

Exosomes are 50–150 nm endocytic vesicles, carrying specific bioactive molecules that are secreted by multiple kinds of cells (90). Such small vesicles derived from tumor cells, which are called tumor-derived exosomes (TEX), are believed to be a new way for tumor cells to communicate with stromal cells (91, 92). Recently, different cell-derived exosomes have been isolated in HNSCC, including TEX and T cell-derived exosomes, and are considered to be associated with immune suppression in cancer (93). Compared with healthy people, HNSCC patients have higher levels of various exosomes that carry inhibitory proteins in plasma, such as PD-L1, CTLA-4, and cyclooxygenase-2 (COX-2), which can mediate immune suppression (94). Besides, PD-L1-positive exosomes were related to the disease activity, UICC grade, and lymph node levels of HNSCC patients. In contrast, sPD-L1 in plasma and PD-1-positive exosomes had no relation with clinicopathological features. Furthermore, exosomes carrying high levels of PD-L1 suppressed CD8+T cell activity. Thus, PD-L1+ exosomes can act as markers of tumor progression (26). The functional differences between exosomes derived from different cells and the underlying mechanism are still worthy of further study.

The Clinical Application of PD-1/PD-L1 Inhibitors in HNSCC

There have been two PD-1 inhibitors approved by the FDA to treat advanced HNSCC so far—Nivolumab and Pembrolizumab. Besides, several clinical trials related to PD-L1 inhibitors—Durvalumab and Atezolizumab, have been completed or are still ongoing. To date, PD-1/PD-L1 blockade has been shown to reduce tumor growth and achieve durable tumor regression in HNSCC.

Nivolumab

Nivolumab is a high affinity, fully human, IgG4 monoclonal antibody that inhibits the binding of PD-L1 to both PD-1 and CD80. In phase III clinical trial CheckMate141, Nivolumab showed a benefit on OS and lower toxicity compared to the standard treatment. Thus, in 2016, the FDA approved Nivolumab for the treatment of recurrent/metastatic HNSCC with or without PD-L1 expression. In this trial, compared with standard therapy (methotrexate, docetaxel, or cetuximab), Nivolumab prolonged median overall survival(mOS) of patients (7.5 vs. 5.1 months), but did not affect median progression-free survival (mPFS). The ORR in the Nivolumab group and standard therapy was 13.3 and 5.8%. The incidence of grade 3-4 adverse events (AEs) was 13.1 and 35.1%, respectively. Also, it was preliminarily observed that PD-L1-positive (cut-off ≥1%) and p16-positive tumors are more likely to benefit from nivolumab monotherapy (95).

Pembrolizumab

In the phase I trial KEYNOTE-012, 60 HNSCC patients whose PD-L1 expression was positive were enrolled and then treated with Pembrolizumab monotherapy. 38% (23 of 60) of patients were HPV-positive, and 62% (37 of 60) were HPV-negative. The ORR was 18% (8 of 45 patients) in all patients, 25% (4 of 16 patients) in HPV-positive patients, and 14% (4 of 29 patients) in HPV-negative patients, which showed that HPV-positive HNSCC had a better curative effect. Besides, the mOS was 13.0 months, and the duration of response was ~53 weeks. Seventeen percentage of patients experienced ≥3 drug-related AEs, and there were no drug-related deaths, which indicated that Pembrolizumab was well-tolerated (14).

In the phase II trial KEYNOTE-055, 171 patients with progressed HNSCC within 6 months were treated with pembrolizumab. Among all patients, the HPV positive rate was 22%, and the PD-L1 positive rate was 82%. However, the ORR was 16%, regardless of HPV or PD-L1 status. The mOS was 8 months, and mPFS was 2.1 months. This trial may suggest that the therapeutic benefit of pembrolizumab is not limited to PD-L1 expression level or HPV status, but the validation of broad sample data is still needed (96).

In the phase III trial KEYNOTE-040, pembrolizumab or standard therapy was applied to 495 recurrent or metastatic HNSCC patients, whose disease progressed during or after platinum-based treatment. The ORR was 14.6 and 10.1% of pembrolizumab and standard therapy, respectively. The mOS was 8.4 and 6.9 months, while there was no difference in mPFS (2.1 vs. 2.3 months). Patients treated with pembrolizumab had fewer grade ≥3 AEs (13 vs. 36%). Most importantly, among patients with the PD-L1 protein tumor proportion score(TPS) ≥50%, pembrolizumab showed longer mOS (11.6 vs. 6.6 months), as well as mPFS (3.5 vs. 2.2 months) (15).

Following these studies, B. Burtness et al. conducted a phase III trial KEYNOTE-048 in which 882 patients were enrolling, comparing the curative effect of pembrolizumab or pembrolizumab combined with chemotherapy (P + C) vs. EXTREME (E, cetuximab + chemotherapy) for recurrent/metastatic HNSCC. Besides, this trial divided subgroups based on tumor PD-L1 expression levels (CPS ≥20 or CPS ≥1). Regardless of the PD-L1 degree, the E group had a better ORR (36 vs. 17%), but a higher incidence of grade ≥3 AEs (83 vs. 55%) than pembrolizumab monotherapy. Also, pembrolizumab monotherapy significantly improved OS over E in the PD-L1-positive populations but showed no difference in the total population. Moreover, this clinical trial suggested that PD-1 monotherapy could be applied for patients with PD-L1 positivity. However, for those patients with PD-L1-negative HNSCC, PD-1 antibody plus chemotherapy could achieve better survival benefits (16).

Durvalumab

Durvalumab is one of the PD-L1 inhibitors which has not been approved for treating HNSCC by FDA, but the related clinical trials are underway (97). Segal et al. conducted a phase I/II trial that applied Durvalumab to 62 recurrent/metastatic HNSCC patients in a basket trial, including different solid tumor entities. The mOS was 8.4 months, and ORR was 12%. Drug-related AEs occurred in 59.7% and were grade 3–4 in 9.7%. However, mPFS did not differ by HPV status or smoking history in this trial, probably due to the insufficient sample size of patients (98).

Zandberg et al. conducted the phase II trial HAWK study, PD-L1-positive recurrent/metastatic HNSCC patients were treated with Durvalumab monotherapy. All enrolled patients (n = 112) had confirmed PD-L1-high expression (defined as ≥25% of tumor cells expressing PD-L1). ORR was 16.2% for all evaluable patients, 29.4% for HPV-positive patients and 10.9% for HPV-negative patients. The OS and mPFS were 7.1 and 2.1 months. Grade ≥3 AEs were 8.0%, and none led to death (18).

Conversely, the randomized, open-label, phase II CONDOR study, using Durvalumab, Tremelimumab (CTLA-4 inhibitors), and a combination of both to treat advanced HNSCC. PD-L1 tumor expression was low or negative in all 267 patients. ORR was 7.8, 9.2, and 1.6% in the combination arm, Durvalumab, and Tremelimumab; mOS for all patients treated was 7.6, 6.0, and 5.5 months, respectively. Grade ≥3 AEs occurred in 15.8, 12.3, and 16.9% (99). The results of the above studies show that PD-L1 and HPV-positive patients are more likely to benefit from PD-1/PD-L1 blockade.

Atezolizumab

Atezolizumab is another PD-L1 monoclonal antibody that can exert antitumor effects through blocking PD-L1. In a phase I basket trial, Atezolizumab was applied to treat patients with advanced solid malignancies or hematologic malignancies, including thirty-two HNSCC patients whose disease was previously treated and then advanced. With no regard to HPV status or PD-L1 expression, the ORR was 22%. Besides, mOS was 6.0 months, and mPFS was 2.6 months. The incidence of grade ≥3 AEs was 13% (100).

Combination Therapy of HPV Vaccine and PD-1 Blockade

Although patients with HPV-positive HNSCC have a relatively higher response rate to PD-1/PD-L1 inhibitors, it still does not exceed 30% (14, 18, 101). As mentioned before, most patients with HPV-positive tumors exhibited a more robust adaptive immune response triggered by HPV antigens (102). Therefore, some studies have explored whether combination with HPV vaccines could increase the response rate of PD-1/PD-L1 inhibitors in patients with HNSCC so that more people can benefit from this. Sun et al. found that PD-L1 blockade enhanced the anti-tumor immune response of an E7 antigen-specific protein vaccine in vivo by mediating M1-like polarization in macrophages and DCs development (103). A study found that E6/E7-targeted vaccine treatment can expand tumor-specific T cells and reduce tumor burden. Tan et al. indicated that combination therapy of the E6/E7-targeted vaccine and PD-L1 antagonist could more effectively control tumor growth and improve the survival of mice with HNSCC (104). Another study also showed that the combination of HPV E6/E7 vaccines and PD-1 inhibition could effectively inhibit tumor growth and reduce PD-L1 expression (105). In phase II clinical trial, 24 patients with HPV-positive cancer were treated with therapeutic HPV vaccines and PD-1 antagonist—Nivolumab. The ORR was 33%, and mOS was 17.5 months, which was better than PD-1 inhibitors alone in similar patients (106). Although the response rate had been improved slightly by this combination therapy, there were still a large number of patients who did not respond, suggesting the underlying mechanism is worthy of further exploration, and randomized clinical trials with more evaluable patients are also needed.

Conclusion and Perspective

Recently, PD-1/PD-L1 inhibitors have been widely approved by the FDA for a variety of solid tumors and achieved inspiring outcomes. For patients with advanced HNSCC that are ineffective with traditional therapy, PD-1 or PD-L1 monoclonal antibodies show their advantages, with a moderate response and better drug-tolerance. However, there are still a majority of patients who could not benefit from these inhibitors. PD-L1 protein is over-expressed in HNSCC tissues above 50%, but always only 15% of patients can respond. Even some studies have shown disease progression after the treatment of the PD-1 antibody. In a study of recurrent or metastatic HNSCC, some patients treated with PD-1 inhibitors experience hyper-progression, which was associated with locoregional recurrence and shorter progression-free survival (107). For oral premalignant lesions, the animal model showed that although the PD-1 antibody stabilizes the disease at an early stage, after a while, it still failed with continued lesion progression (108). However, it is worth noting that the moderate ORR of PD-1/PD-L1 inhibitors may be the result of the application for the treatment of advanced HNSCC patients, where traditional treatment options have failed and are unlikely to improve the outcomes by further treatment.

Therefore, it is crucial to understand whether other inhibitory molecular pathways cooperate with PD-1/PD-L1 to maintain suppressed cellular immunity, and clarifying the cross-talk between these pathways and maximizing the effectiveness of PD-1 inhibitors are worthy of further study. For example, Tim-3 represents a highly dysfunctional state of TILs. A study found that PD-1/PD-L1 blockade resulted in further Tim-3 up-regulation on TILs through PI3K/Akt pathway, leading to immune escape and adaptive resistance to PD-1 or PD-L1 monotherapy (109). Similarly, TIGIT/CD155 pathway also contributes to the “exhaustion” state of TILs. TIGIT was over-expressed on Tregs of HNSCC patients and mouse models, and PD-1/PD-L1 blockade up-regulated TIGHT expression on Tregs, which was associated with immune suppression (110). It was reported that PD-1 blockade combined with TLR agonists could activate TAMs and induces tumor-specific adaptive immune responses (111). Moreover, PD-1/PD-L1 blockade enhances cetuximab-based cancer immunotherapy and reverses CD8+ TILs dysfunction (112). Down-regulation of major histocompatibility complex (MHC) class I is a tumor immune evasion mechanism. MEK inhibitor Trametinib could enhance both MHC class I and PD-L1 expression in human HNSCC cell lines, which was mediated by STAT3 activation. At the same time, combined Trametinib with PD-L1 blockade increased CD8+ T cell infiltration in the tumor microenvironment and delayed tumor growth (113).

Additionally, considering the cost and toxicity of immune therapy, it is necessary to search for stable and useful biomarkers, including the PD-1 and PD-L1 expression level, HPV status, tumor mutation burden (TMB) and immune infiltration situation, etc., in order to select the most appropriate individuals to administer the drug and optimize the therapeutic regimen (114–118). Meanwhile, more indications for the use of PD-1/PD-L1 inhibitors in HNC, such as early stages HNSCC or salivary gland tumors are needed for further investigation.

In summary, there is a growing interest in the mechanism of the PD-1/PD-L1 pathway involved in tumor progression, and immune checkpoint blockade has achieved initial success in patients with recurrent or/and metastatic HNSCC. Understanding the expression of PD-1 and PD-L1 in tumor cells is beneficial to our understanding of the biological behavior of HNSCC. Still, their expression and function in immune-infiltrating lymphocytes also need further study. Further research shouldwork toward finding populations that can respond to PD-1/PD-L1 blockade and combining with other molecular targets to improve the response rate and prolong response duration.

Author Contributions

X-wQ and JJ were mainly responsible for the manuscript writing. XP, M-cH, and Y-jT were assisted in writing. X-hL and Y-lT provided suggestions on the ideas and performed the final corrections.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.